Depression and sleep: pathophysiology and treatment by Thase, Michael E.
leep is a critical aspect of the pathophysiology
and treatment of depression at multiple levels.At the most
superficial, descriptive level, a large majority of people
with depressive disorders report disturbed or altered sleep
and,as such,essentially all diagnostic criteria for depres-
sion include sleep disturbances as a key feature.
1 Insomnia
in particular has been described in first-hand accounts of
depression since antiquity.
2 Hypersomnia,although a less
prevalent symptom than insomnia,is an important feature
of the so-called atypical subtype of depression,as well as
a not-uncommon feature of depression in younger people,
particularly those with bipolar affective disorder.
3,4
Although vulnerability to mood disorders are not usually
simply a consequence of sleep disturbances,longitudinal
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This review examines the relationship between sleep and depression. Most depressive disorders are characterized by
subjective sleep disturbances, and the regulation of sleep is intricately linked to the same mechanisms that are impli-
cated in the pathophysiology of depression. After briefly reviewing the physiology and topography of normal sleep,
the disturbances revealed in studies of sleep in depression using polysomnographic recordings and neuroimaging
assessments are discussed. Next, treatment implications of the disturbances are reviewed at both clinical and neuro-
biologic levels. Most antidepressant medications suppress rapid eye movement (REM) sleep, although this effect is nei-
ther necessary nor sufficient for clinical efficacy. Effects on patients’ difficulties initiating and maintaining sleep are
more specific to particular types of antidepressants. Ideally, an effective antidepressant will result in normalization of
disturbed sleep in concert with resolution of the depressive syndrome, although few interventions actually restore
decreased slow-wave sleep. Antidepressants that block central histamine 1 and serotonin 2 tend to have stronger
effects on sleep maintenance, but are also prone to elicit complaints of daytime sedation. Adjunctive treatment with
sedative hypnotic medications—primarily potent, shorter-acting benzodiazepine and -aminobutyric acid (GABA A)-
selective compounds such as zolpidem—are often used to treat associated insomnia more rapidly. Cognitive behav-
ioral therapy and other nonpharmacologic strategies are also helpful.     
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5,6 and may herald relapses in
patients with recurrent illness.
7At the most basic level,the
brain stem and thalamic nuclei that regulate sleep and the
limbic mechanisms that modulate affective arousal are
implicated in the pathophysiology of both sleep distur-
bances and depressive disorders.
8,9 To truly understand
depression thus requires knowledge of sleep and its dis-
orders and,conversely,physicians caring for patients com-
plaining of insomnia must be cognizant of the relationship
with depression.
The topography of normal sleep
Sleep regulation
As excellent detailed reviews are available elsewhere,
10,11
this section will only briefly summarize the basic aspects
of the physiology of normal sleep.Sleep is regulated by
three interrelated processes.First,there is the circadian
sleep-wake cycle,which in human beings is entrained to
both the solar photoperiod and the 24-hour clock.In addi-
tion to wakefulness and sleep,the activity of several hor-
mone axes (ie,secretion of cortisol,growth hormone,and
melatonin) and core body temperature follow this circa-
dian rhythm. Normally, sleep is most likely to occur
between sundown and sunrise,following the nocturnal rise
of melatonin and coincident with reductions in core body
temperature and cortisol secretion; increased, pulsatile
release of growth hormone is typically greatest during the
first hours following sleep onset. Several biological
“clocks”or pacemakers regulate these rhythms,including
one located in the suprachiasmatic nucleus (SCN) of the
anterior hypothalamus.Through this nucleus,the changes
in light intensity that demarcate the transitions of day and
night help to synchronize circadian rhythms. Whereas
bright white light suppresses secretion of melatonin,the
onset of darkness elicits hormonal release from the pineal
gland,which serves to increase sleepiness.
The second process that regulates sleep is homeostatic,in
that sleep has a restorative function that offsets the dele-
terious cognitive and physiological consequences of sus-
tained wakefulness (see, for example, Borbely
12).
Specifically,a sufficient amount of sleep is necessary for
optimal functioning,and sleep deprivation is now known
to be associated with broad neurobehavioral deficits.
13
Although the specific neurochemistry has not yet been
clarified,a sleep propensity factor (sometimes referred to
as Process S) is presumed to accumulate during wakeful-
ness and be used up during deep sleep.
12
The third regulatory process involves the ultradian rhythm
that consists of alternating periods of rapid eye movement
(REM) and nonREM sleep.This characteristic was first
identified more than 50 years ago, when electroen-
cephalograms (EEGs) began to be used to record brain
activity during sleep.
14 For the next four decades, as the
methods were developed, what is now known as the
polysomnogram—consisting of technically simple,simul-
taneous recordings of electroencephalogram (EEG),eye
movements,and muscle activity—served as the best means
to study the dynamic neurobiology of sleep.
Basic research has established that the reciprocal activities
of thalamocortical and corticothalamic circuits mediate the
regular alternation of nonREM and REM sleep.
10,11
Among the complex neurochemical mechanisms impli-
cated in sleep,cholinergic projections for neurons in the
dorsal tegmentum elicit the onset of REM sleep and sero-
toninergic neurons (originating from the dorsal raphe
nucleus) and noradrenergic neurons (originating from the
locus ceruleus) inhibit REM sleep.
Sleep architecture
Research using polysomnograms led to a reliable, five-
stage “architecture”of sleep.As noted above,the first clas-
sification was based on the presence or absence of REM
sleep.REM sleep is characterized by high-frequency,low-
voltage EEG activity and bursts of rapid movements of
the eye muscles, coupled with atonia of major skeletal
muscles and penile erections or vaginal lubrication.Such
a curious juxtaposition of characteristics led some early
researchers to refer to REM sleep as paradoxical sleep.
A healthy younger person’s normal night of sleep typically
includes four to five distinct REM periods occurring at 90-
minute intervals,accounting for about 20% of total time
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Selected abbreviations and acronyms
5-HT serotonin
BZ benzodiazepine




REM rapid eye movement
SNRI serotonin-norepinephrine reuptake inhibitor
SSRI selective serotonin reuptake inhibitor
TCA tricyclic antidepressantspent asleep (TSA).REM periods typically grow longer
and more intense across a normal night of sleep.Thus,if
the accumulated homeostatic sleep “debt”is largely repaid
by end of the second nonREM sleep period,there is a rec-
iprocal,increasing “pressure”for REM sleep that builds
progressively until the individual wakes up.
Originally called “dream sleep”because of the temporal
association with most dreaming,REM sleep is still thought
to serve an important role in consolidation of memory and
processing of affectively charged cognitions.
Parenthetically,an abnormally increased amount of REM
sleep time or REM sleep intensity could be the result of a
functional adaptation (ie,an increased need for affective
processing),a relative increase in cholinergic neurotrans-
mission,or decreased inhibitory input from serotoniner-
gic or noradrenergic nuclei.
Most of the night is spent in nonREM sleep,which is fur-
ther subdivided into four progressively deeper stages.
Stage I sleep is the lightest stage of sleep,and functionally
serves as the transition between drowsy wakefulness and
deeper sleep stages. Ideally, less than 5% of the night is
spent in stage I sleep.Stage II sleep is defined by the emer-
gence of K-complexes and sleep spindles, and typically
accounts for more than one half of a night’s sleep.The
deepest states of sleep, stage III and stage IV sleep, are
characterized by undulating, desynchronized delta (or
slow) waves.Such deep sleep is typically concentrated dur-
ing the first two nonREM periods.The normal amount of
deep sleep is highly age-dependent,and few individuals
over age 50 spend more than 5% of the night in stage III
and stage IV sleep.
For a healthy young person,the first progression through
the four nonREM sleep stages (ie,stage I through stage
IV) typically takes 70 to 100 minutes; the elapsed time
from sleep onset until the beginning of the first REM
period is called REM latency.With normal aging,REM
latency characteristically grows shorter because of the loss
of slow-wave sleep,and with advanced age the entire night
may be spent in only three sleep stages (stage I,stage II,
and REM).
Sleep architecture is somewhat sex-dependent and, as
noted above,highly influenced by aging.Women tend to
have a greater percentage of deep sleep than men,partic-
ularly prior to menopause.Across decades of aging,sleep
typically becomes lighter, with more awakenings and
awake time.There is also a progressive loss of slow-wave
sleep with aging,which typically occurs in men at an ear-
lier age than women. Sleep quality may be further
adversely affected by age-dependent increases in sleep-
disordered breathing.
Beyond the direct relationship between sleep deprivation
and neurobehavioral function,recent research has linked
disturbances of sleep to other important health risks.For
example,insomnia is associated with an increase in the cas-
cade of cytokines and other “markers”of inflammatory
processes.
15 Disturbed sleep also is associated with alter-
ations in glucose metabolism and may represent a risk fac-
tor for development of obesity
16 and adult-onset diabetes
mellitus.
17 It is not surprising,then,that research has estab-
lished that “healthy”sleep is a reliable correlate of sub-




The availability of modern imaging methods has permit-
ted a more functional characterization of selected aspects
of the topography of sleep.
8,9,19,20Although technological
limitations in the measurement of cerebral blood flow or
regional shifts in metabolic activity have necessitated
focusing on key transition points,such as from waking to
nonREM sleep or from nonREM to REM sleep,interest-
ing findings are emerging.Consistent with the homeosta-
tic function of sleep,blood flow and glucose metabolism
globally decrease with the transition from waking to sleep-
ing, with the greatest decline during deep sleep.
8,9,19,20
Conversely,individuals with primary insomnia have been
found to have relatively greater cerebral metabolism dur-
ing nonREM sleep.
21The onset of REM sleep is associated
with a sharp increase in blood flow and cerebral metabo-
lism,including—but not limited to—limbic and pontine
structures.
22
Alterations of sleep neurophysiology 
in depression
Most depressed people show evidence of one or more
alterations in sleep neurophysiology;multiple disturbances
in polysomnographic recordings of sleep are evident in
about 45% of depressed outpatients and 80% of more
severely depressed inpatients.
1,23 About 10% of never-
depressed people have “false-positive” sleep profiles.
23
With respect to “false-positive” profiles, less severely
depressed patients—particularly younger depressed
patients with atypical features such as hypersomnolence—
are overrepresented.Although hypersomnolent depressed
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nificant minority do manifest increased REM sleep inten-
sity.
24,25 It has been suggested that the tendency for long
total sleep time may reflect a compensatory phenomenon
that permits more slow-wave sleep across the night.
The most common disturbances documented in visually
scored polysomnograms are:decreased sleep efficiency (a
composite measure that takes into account difficulty
falling asleep,nocturnal awakenings,and early-morning
awakening), decreased slow-wave sleep (which reflects
decreased stage III and stage IV sleep time), reduced
REM latency,and increased REM intensity (which is typ-
ically expressed as increased REM density, a ratio of a
measure of REM intensity divided by time spent in REM
sleep).
1,23,24 Depressed men also have a decrease in noctur-
nal penile tumescence,which is paradoxical given the over-
all increase in REM sleep time.
25 Computer-scored abnor-
malities include a decrease in slow wave counts during the
first nonREM period and an increase in REM counts dur-
ing the first REM period.
25 None of these disturbances are
truly specific to depression and are also observed in other
psychopathologic states.
24 Increased REM sleep indices,
for example,have been observed in eating disorders,some
anxiety disorders,schizoaffective disorder,and borderline
personality disorder.Reduced REM latency and increased
REM density also characterize narcolepsy.Premature loss
of slow-wave sleep and reduced REM latency are also
common in chronic forms of schizophrenia,sleep apnea,
alcoholism,and degenerative central nervous system dis-
orders such as presenile dementia.
24
Studies of depression utilizing neuroimaging methods doc-
ument increased global cerebral metabolism during the
first nonREM sleep period;there is also a relative decrease
in cerebral blood flow and glucose metabolism during the
transition from nonREM to REM sleep.
19,20These abnor-
malities are thought to reflect nocturnal hyperarousal,
which is particularly evident in frontal and prefrontal cor-
tical structures.
20
Longitudinal studies of sleep disturbance in depression
indicate that some features do not fully normalize follow-
ing recovery.
1The most state-independent or persistently
abnormal disturbances are decreased slow-wave sleep and
reduced REM latency,which show some degree of heri-
tability
26 and,as such,may represent vulnerability traits.
Increased REM density and decreased sleep efficiency are
more reversible and therefore are considered to be state-
dependent. Consistent with this view, patients with
increased REM density and poor sleep efficiency are more
likely to manifest various indices of hypercortisolism,
another state-dependent correlate of severe depression.
27
In one longitudinal study,there was about a 50% chance
that an abnormal sleep profile (on the basis of reduced
REM latency,increased REM density,and decreased slow-
wave sleep) would normalize following 16 weeks of cog-
nitive behavior therapy.
28As research by our group sug-
gested that such sleep abnormalities predicted a poorer





they may help to define a neurobiological profile that is
more responsive to somatic antidepressant interventions.
Antidepressants and sleep neurophysiology
Although longitudinal studies of patients withdrawn
from antidepressant medications suggest that pharma-
cotherapy,like psychotherapy,can result in a partial nor-
malization of sleep disturbances,
1 antidepressant med-
ications also have pronounced, direct effects on sleep
neurophysiology that are also evident in studies of
healthy individuals.
31 Most antidepressants directly sup-
press REM sleep, as evident by a marked (ie, >50%)
reduction in REM time and prolongation (ie,>150%) of
REM latency.
1,31 Suppression of REM sleep is evident
within hours of beginning therapy with both selective
serotonin reuptake inhibitors (SSRIs) and relatively
selective norepinephrine reuptake inhibitors such as
desipramine or maprotiline.
31 Pronounced REM sup-
pression also is evident during treatment with nonselec-
tive monoamine oxidase inhibitors such as phenelzine
32
and tranylcypromine.
33 Mirtazapine, which enhances
noradrenergic activity via blockade of inhibitory α2
receptors,likewise suppresses REM sleep.
34Thus,as anti-
depressants with diverse mechanisms of action suppress
REM sleep,it is likely that potent modulation of either
noradrenergic or serotoninergic neurotransmission
underpins this effect.
Among currently available antidepressants,there are only
a handful that do not suppress REM sleep—trazodone,
bupropion,and nefazodone.
1,31A fourth compound,trim-
ipramine,which is a weaker REM suppressor than the rest
of the tricyclics,does not exert much suppressant effect at
lower doses.
35The common link among these medications
is that none of the three has potent,direct effects on nor-
epinephrine or serotonin neurotransmission.In one small
study,bupropion therapy actually resulted in an intensifi-
cation of REM sleep in a subset of patients.
36 It is not clear
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able to the proposed mechanism of action of bupropion
(ie,potentiation of dopamine neurotransmission) or if it is
simply an epiphenomenon of an enhancement of positive
affectivity.
37
Beyond improvements in sleep efficiency directly result-
ing from resolution of the depressive syndrome,some anti-
depressants also exert more rapid beneficial effects on ini-
tiation and/or maintenance of sleep.
1,31As discussed below,
these effects are largely attributable to blockade of hista-
mine (H)1 and/or serotonin (5-HT)2 receptors.Whereas
REM suppressant effects tend to predict subsequent anti-
depressant effects,at least in studies employing tricyclic
antidepressants,
38 early improvements in sleep efficiency
generally are not correlated with treatment response.In
fact, effective therapy with potent and selective
monoamine reuptake inhibitors can actually worsen some
patients’ ability to initiate or maintain sleep, which can
slow or impair treatment response.
1,31
In contrast to the reliable effects of antidepressants on
REM sleep and,to a lesser extent,patients’ ability to ini-
tiate and maintain sleep,antidepressant medications do
not reliably increase hand-scored slow-wave sleep.
1,31
Given the importance of deep sleep as a neurobiologic
marker of well-being,this is a target for future research.
As discussed subsequently,some medications used to aug-
ment antidepressant effects, including lithium and the
atypical antipsychotic olanzapine, have been shown to
increase both hand- and computer-scored slow-wave
sleep.
1
Management of depressive insomnia
It would be an optimal solution if the same intervention
that was used first-line to treat the depressive disorder also
produced rapid and complete relief of the associated
insomnia.This ideal is far from being realized,however,
and in the following sections the relative merits and limi-
tations of antidepressants, sedative-hypnotics, nonpre-
scription sleep aids,and cognitive-behavior therapy are
discussed.
Antidepressant pharmacotherapy
Despite the fact that there is compelling evidence that
complaints of insomnia are reliably reduced by a wide
range of antidepressants—when treatment is effective—
there is also evidence that persistent insomnia is one of the
more common residual symptoms of incompletely remit-
ted depression.
39,40This has potentially ominous implica-
tions because residual depressive symptoms are one of the
best-validated predictors of subsequent relapse risk,
41,42 as
well as persistent functional disability.Therefore,ensuring
that patients taking antidepressants experience complete
relief of associated insomnia is one of the best strategies
to increase the likelihood that sustained remission and,
subsequently,full recovery are realized.
The problem of persistent or incompletely remitted sleep
disturbance may be greater today than in previous
decades because of changes in the pharmacology of the
most commonly used antidepressants. Specifically,
whereas most of the tricyclic antidepressants (TCAs)—
the mainstay of pharmacotherapy from the early 1960s
until the late 1990s—had nonspecific sedative hypnotic
properties, the SSRIs and serotonin-norepinephrine
reuptake inhibitors (SNRIs) do not.
1,31 In fact, it is not
common for increased complaints of insomnia to accom-
pany the first few weeks of pharmacotherapy with SSRIs
such as fluoxetine
43 or the SNRI venlafaxine.
44 Increased
nocturnal arousal is presumed to be caused, at least in
part, by stimulation of postsynaptic serotonin type 2 
(5-HT2) receptors.
1,31
If the antidepressant-induced exacerbation of insomnia is
not too marked,watchful waiting may be all that is neces-
sary,as some degree of neuronal accommodation/desen-
sitization often develops over several weeks of therapy.
It is also true that,as the depressive syndrome lifts,patients
are less likely to complain of insomnia,even in the absence
of objective improvements in sleep neurophysiology.This
is not always the case,however,and pharmacoepidemio-
logic surveys indicate that at least one third of patients tak-
ing modern reuptake inhibitors receive concomitant seda-
tive hypnotic medications.Although controlled data are
sparse,there is evidence that combining benzodiazepines
(BZ)
45-47 or the selective γ-aminobutyric acid (GABA) type
A receptor antagonist zolpidem
48 with antidepressants
from the beginning of therapy will result in more reliable
relief of the associated sleep disturbance and hasten
improvement of the overall depressive syndrome.
Although results of controlled studies with other GABA
A selective agents such as zoplicone,eszoplicone,and zale-
plon are not in the published literature, it is likely that
these medications are also beneficial in combination with
antidepressants.
49
Two members of the now otherwise forgotten “second
generation”of antidepressants,trazodone and mianserin
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widely used as adjuncts to SSRIs and SNRIs to relieve
insomnia.
1,50 Both medications are available in inexpensive
generic formulations and—unlike conventional sedative-
hypnotics—their longer-term use is not hampered by con-
cerns about tolerance or potential for abuse.Moreover,
there is ample clinical experience to support the use of
low-dose therapy with trazodone or mianserin to manage
insomnia that persists despite SSRI/SNRI therapy.Despite
these strengths,neither medication has been extensively
studied in combination with modern reuptake inhibitors
nor—truth be told—do these compounds have the safety
track record of the BZs.
1,50
Among the modern antidepressants, only two reliably
improve the insomnia associated with depression:nefa-
zodone—a direct descendent of trazodone—and mir-
tazapine,a close “cousin”of mianserin.
1,31 Neither of these
neurochemically distinct compounds have much
inhibitory effect on monoamine uptake transporters,but
both are potent antagonists of postsynaptic 5-HT2 recep-
tors. Mirtazapine also has early, nonspecific sedative
effects via potent antagonism of H1 receptors.The rela-
tively favorable sleep effects of nefazodone were demon-
strated versus fluoxetine in a large multicenter study that
included pre-post polysomnograms.
43 Because the study
was only 8 weeks long,however,questions persist about
whether the advantage of nefazodone would have per-
sisted across months of continuation phase therapy.
Whether nefazodone would show comparable advan-
tages versus SSRIs other than fluoxetine also remains an
open question.
35 Mirtazapine was likewise shown to result
in more rapid and favorable relief of insomnia symptoms
in a pair of head-to-head studies versus venlafaxine,
51,52 as
well as versus fluoxetine in a small study that included
polysomnographic monitoring.
34
Despite the ubiquity of sleep disturbances associated with
depression and the empirically established advantage of
these compounds for depressive insomnia,neither nefa-
zodone nor mirtazapine were ever widely accepted as first-
line antidepressants in most countries.Nefazodone was
perceived to be more difficult to titrate and somewhat less
effective than the reuptake inhibitors
1 and subsequent
recognition of a rare but potentially catastrophic hepatic
toxicity resulted in its withdrawal from the market in many
countries (although it is still available in generic formula-
tions in the US).Mirtazapine,while judged to be at least
as effective as SSRIs,
53 was probably not more widely used
because of the frequency of side effects mediated by H1
blockade,including increased appetite,weight gain,and
excessive daytime sedation.Because of these side effects,
the major advantage of mirtazapine therapy may well be
limited to patients with more severe depressive episodes
associated with marked insomnia,particularly in later life,
where sleep disturbance and weight loss are more com-
mon problems.
Another novel antidepressant with favorable effects for
sleep, agomelatine,
54 may soon be approved for use
within the European Union.Agomelatine is thought to
have a truly unique mechanism of action, namely ago-
nism of melatonin type 1 (M1) and type 2 (M2) receptors.
Agomelatine is also an antagonist of 5-HT2 receptors.
Early studies with this medication have yielded promis-
ing comparative results.Further research and,even more
importantly,more extensive post-marketing experience
will fully assess its relative merits and limitations.
Augmentation of antidepressants with sedating atypical
antipsychotic medications such as olanzapine and queti-
apine is also sometimes utilized.As reviewed elsewhere,
55
the members of this heterogeneous class of medications
have diverse effects on sleep that undoubtedly include
nonspecific benefits as well as more specific neurophar-
macologic effects.Of note,in one small study olanzapine
augmentation therapy resulted in a substantial increase
in slow-wave sleep time.
56The widespread use of atypical
antipsychotics for management of insomnia is limited by
cost (only the seldom-used clozapine is available in
generic formulations) and the incidence of weight gain
and other metabolic complications,as well as some lurk-
ing concerns about the eventual risk of tardive dyskine-
sia.
Concomitant therapy with sedative-hypnotic 
medications
Among the wide range of sedative-hypnotic medications
still commercially available,only the BZs and the selective
GABA A agonists warrant continued use.
10The BZ class
includes medications that were originally primarily devel-
oped for use as anxiolytics,as well as those marketed as
hypnotics.
57All can be used to reduce sleep latency and
prolong total sleep time,although some members of the
BZ class are clearly better suited for use as hypnotics on
the basis of pharmacokinetic effects (ie,shorter elimina-
tion half-life, rapid absorption, absence of an active
metabolite,and high lipophilicity,which ensures rapid pas-
sage through the blood-brain barrier).There is a small risk
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that a patient who begins therapy with a BZ will develop
dependence,and lethality in overdose does increase when
BZs are ingested in combination with alcohol.
Nevertheless, the reliable efficacy, low cost, and strong
overall safety track record of this class is difficult to sur-
pass,at least for short-term administration.
10,58
The major shortcoming of this venerable class of medica-
tions is that, despite the fact that a subset of patients
requires longer-term therapy,it is not at all clear from stud-
ies of primary insomnia that the BZs’ benefits are sus-
tained,
10,58 perhaps particularly for patients’ longer-term
antidepressant therapy.
59 In fact, in one of the fewer
placebo-controlled,longer-term trials,the beneficial effects
of clonazepam (a potent BZ with an intermediate half-life)
on patients’ sleep complaints were largely limited to only
the first 3 weeks of therapy.
59 In fact, although it took
slightly longer for the patients who were randomly
assigned to receive placebo in combination with fluoxe-
tine to experience relief of insomnia,the two groups had
comparable outcomes after 12 weeks of therapy,on both
depression and subjective sleep disturbance.It is unfortu-
nate that this otherwise well-controlled study did not
include polysomnographic recordings to ascertain if effects
on objective measures of insomnia matched the subjective
changes.Sadly,this study is not unique:despite nearly 20
years of routine clinical use,there does not appear to be a
single controlled study utilizing serial polysomnograms to
assess the effects of combination therapy with an SSRI or
SNRI and BZ in the published literature.
As the BZs were hoped to be better alternatives to the
barbiturates, the GABA A agonists were developed to
improve upon the BZs’ various shortcomings.
10,60
Specifically,these selective agents were developed to work
quickly with minimal residual (ie,hangover) effects,little
interaction with alcohol,and little risk of abuse.Although
the debate is not fully resolved,these medications have
arguably succeeded,at least for concomitant treatment of
patients with milder insomnia.
10,60
In addition to these more “mainstream” hypnotic med-
ications,ramelteon—a novel selective agonist of MT1 and
MT2 receptors—has recently been approved by the US
Food and Drug Administration (FDA) for treatment of
primary insomnia.Placebo-controlled trials have estab-
lished that this medication reliably decreases time to sleep
onset in adults with both transient insomnia as well as
patients with more longstanding problems with primary
insomnia.
61,62When compared with the BZs and GABA A
selective medications,ramelteon has the major advantage
of an apparent lack of abuse potential.In fact,it is the only
currently available FDA-approved hypnotic that is not
classified as a controlled substance.Experience with treat-
ing insomnia associated with depression and other mood
disorders is,to date,quite limited and it would be prema-
ture to consider this promising medication a proven treat-
ment for the sleep disturbances of patients taking antide-
pressants.
Patients with insomnia often self-medicate with over-the-
counter medications and remedies,with range from vari-
ous antihistaminergic compounds (such as diphenhy-
dramine) to “natural” agents such as melatonin and
valerian root.The utility (or,more accurately,the lack of
efficacy) of these nonprescription medications has been
reviewed elsewhere in more detail.
63-65 Suffice it to say that
if a patient warrants treatment for relief of a significant
persistent sleep disturbance,there are a number of more
promising interventions that can be utilized.
Cognitive-behavioral management of insomnia
The past decade has witnessed increased interest in non-
pharmacologic approaches to management of insomnia,
particularly those emphasizing cognitive and behavioral
methods.
65,66 Beyond explicit attention to sleep hygiene,
cognitive behavior therapy (CBT) for insomnia utilizes
stimulus control and arousal reduction techniques.There
is evidence from studies of primary insomnia that com-
prehensive CBT results in short-term improvements that
are—at the least—as effective as pharmacotherapy with
sedative-hypnotics.
67The potentially greatest advantage
of CBT is evident over time,however,as effectiveness is
more durable than pharmacotherapy and benefits persist
after therapy is terminated.
68Thus,although CBT may be
a more costly approach than pharmacotherapy in the
short run,it becomes a cost-effective approach across 6
months or longer. Given the positive experience as a
treatment of primary insomnia,there is a clear need for
studies on the utility of CBT—in combination with anti-
depressant therapy—for patients with major depressive
disorder.
69
It is noteworthy that other models of CBT directed more
broadly at the overall depressive syndrome often fail to
vigorously address insomnia. For example, in one large
comparative study of patients with chronic forms of major
depressive disorder,the antidepressant nefazodone had a
substantial advantage over the cognitive behavior analy-
sis system of psychotherapy for relief of both objective andsubjectively assessed depressive insomnia,even though the
two therapies had comparable overall effects.
70,71 Given the
relatively inconsistent performance of various models of
psychotherapy for treatment of more severe depressive
states
72 it would be prudent for therapists to consider
adding a more specific CBT module to address insomnia.
Conclusions
Sleep disturbances are an integral aspect of depression,at
phenomenologic,pathophysiologic,and therapeutic levels
of inquiry.Improving the understanding of the relation-
ship between sleep disturbances and mood disorders will
only help to clarify the heterogeneity of depression.
Persistent insomnia can reflect incomplete remission of
the depressive episode and/or a side effect of pharma-
cotherapy;in either case it may be an ominous correlate
of vulnerability to relapse.Although no universally effec-
tive strategy is yet available,there are a variety of effective
strategies—both pharmacologic and cognitive-behav-
ioral—that can be used to improve management of insom-
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Depresión y sueño: fisiopatología y 
terapéutica
Esta revisión examina la relación entre sueño y
depresión. La mayoría de los trastornos depresivos se
caracterizan por alteraciones subjetivas del sueño,
y la regulación del sueño está vinculada de manera
compleja con los mismos mecanismos que están
implicados en la fisiopatología de la depresión.
Después de revisar brevemente la fisiología y la topo-
grafía del sueño normal se discuten las alteraciones
que han sido reveladas por los estudios de sueño en
la depresión mediante el empleo de registros poli-
somnográficos y evaluaciones de neuroimágenes. A
continuación se revisan los efectos de las alteracio-
nes tanto a nivel clínico como neurobiológico. La
mayoría de los fármacos antidepresivos suprime el
sueño de movimientos oculares rápidos (REM), aun-
que este efecto no es necesario ni suficiente para la
eficacia clínica. Los efectos sobre las dificultades de
los pacientes para iniciar y mantener el sueño son
más específicos de ciertos tipos de antidepresivos.
Idealmente, un antidepresivo efectivo provocará una
normalización del sueño alterado conjuntamente
con la resolución del síndrome depresivo, aunque
actualmente son pocas las intervenciones que resta-
blecen la disminución del sueño de ondas lentas. Los
antidepresivos que bloquean los receptores centra-
les de histamina1 y serotonina2 tienden a provocar
mayores efectos en la mantención del sueño, pero
también son más proclives a favorecer quejas de
sedación diurna. El tratamiento conjunto con fár-
macos hipnótico sedantes  benzodiazepinas prima-
riamente potentes, de acción corta y  compuestos
selectivos sobre ácido gama amino butírico (GABA
A) como el zolpidem– se utilizan a menudo para tra-
tar más rápidamente el insomnio asociado. También
resultan útiles la terapia cognitivo conductual y otras
estrategias no farmacológicas.
Dépression et sommeil : physiopathologie et
traitement
Cet article se penche sur les relations entre le som-
meil et la dépression. La plupart des troubles dépres-
sifs se caractérisent par des troubles subjectifs du
sommeil, la régulation du sommeil étant étroitement
liée aux mécanismes impliqués dans la physiopatho-
logie de la dépression. Après un court rappel de la
physiologie et de la topographie du sommeil normal,
les troubles mis en évidence dans les études sur le
sommeil au cours de la dépression grâce à des enre-
gistrements polysomnographiques et à des évalua-
tions de neuro-imagerie sont étudiés. Puis les impli-
cations thérapeutiques des troubles aux niveaux
cliniques et neurobiologiques sont examinées. La
plupart des antidépresseurs suppriment les mouve-
ments oculaires rapides (MOR), bien que cet effet ne
soit ni nécessaire ni suffisant pour une efficacité cli-
nique. Les effets sur les difficultés du patient à s’en-
dormir ou à prolonger son sommeil sont plus spéci-
fiques de certains types d’antidépresseurs.
Idéalement, un antidépresseur efficace permettra de
normaliser les troubles du sommeil tout en traitant
le syndrome dépressif, bien que, en réalité, il existe
très peu de mécanismes restaurant le sommeil à
onde lente diminué. Les antidépresseurs qui blo-
quent l’histamine 1 et la sérotonine 2 centrales ont
un effet plus important sur le maintien du sommeil,
mais sont aussi connus pour induire une sédation
diurne. Un traitement supplémentaire avec des hyp-
notiques sédatifs – efficaces d’emblée, des benzo-
diazépines de plus courte durée d’action et des com-
posés sélectifs de l’acide  aminobutyrique (GABA A)
comme le zolpidem- est souvent utilisé pour traiter
l’insomnie associée plus rapidement. Un traitement
cognitivocomportemental et d’autres stratégies non
pharmacologiques sont également utilisés.
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